Esperion Therapeutics (NASDAQ:ESPR) Earns Buy Rating from Needham & Company LLC tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.
Esperion Therapeutics (ESPR) Buy Rating Reaffirmed at Needham & Company LLC dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Investment analysts at Zacks Research cut their Q4 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued on Monday, April 29th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will earn $0.14 per share for the quarter, […]
This newsletter reports on U.S. legal matters relevant to Japanese companies. This edition covers U.S. court cases and cross-border transactions from the winter of 2023-24. Among other things.
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) has received a consensus recommendation of “Hold” from the five research firms that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month target price among […]